Why Your Peptide Protocol “Stopped Working”

Your protocol was working. Results were visible. Then it plateaued, or worse, reversed. The community answer is usually “tolerance” or “bunk peptides.” But true pharmacological tolerance to peptides like BPC-157 or GH secretagogues is rare at standard doses. The real causes are operational.

1. Compound Degradation

Reconstituted peptides are fragile. They degrade from:

• Temperature excursions (left on counter for 30 minutes, fridge door shelf that's warmer)
• Age (past the 14-28 day stability window)
• Light exposure (clear vial on a visible fridge shelf)
• Repeated needle punctures introducing contaminants

Check: When did you reconstitute this vial? If you can't answer precisely, this is probably your problem.

2. Injection Site Absorption Loss

Lipohypertrophy (tissue thickening from repeated injection) reduces absorption by up to 25%. You inject the same calculated dose, but your body receives 75% of it. The remaining 25% pools in damaged tissue and never reaches systemic circulation.

Check: Palpate your injection sites. If any feel firmer or lumpier than tissue you've never injected, you have absorption loss.

3. Timing Drift

GH secretagogues are timing-sensitive. Injecting CJC-1295/Ipamorelin “before bed” at 10 PM vs. midnight creates different GH pulse profiles. Over weeks, “roughly the same time” drifts enough to change outcomes.

For stacks with interaction windows:

• Food within 30 minutes of GH secretagogue blunts the pulse
• Two peptides too close together can compete for receptor binding
• 5/2 cycling that drifts by a day changes your effective on-period

Check: Are you logging exact injection times? “Morning” is a 4-hour window. Without timestamps, you can't identify timing drift.

4. Invisible Inventory Gaps

You ran out of one compound for 3 days while waiting for delivery. You continued the other compounds in your stack. When the missing compound arrived, you resumed. The gap felt minor.

But some protocols depend on compound synergy:

• BPC-157 + TB-500 have complementary healing mechanisms. Removing one reduces the stack's effectiveness beyond just the missing compound.
• CJC + Ipamorelin work synergistically on GH release. Running one without the other for a week is different from a planned rest day.

Check: Have you had any unplanned gaps in any compound? Even 2-3 days can reset synergistic effects that took weeks to build.

5. Dose Calculation Errors

This one is uncomfortable: you might be injecting the wrong amount. Common errors:

• Wrong concentration assumption - You reconstituted with 2ml but calculated based on 1ml, injecting half the intended dose
• Syringe reading error - U-100 vs U-50 syringes have different unit markings. 10 units on a U-100 is 0.1ml. 10 units on a U-50 is 0.2ml.
• New vial, different concentration - Reconstituted the replacement vial with a different water volume but kept drawing the same units
• Dead volume accumulation - After 15+ draws from a vial, dead volume losses mean the last few injections are underdosed

Check: Recalculate your current dose from scratch. Vial size, water added, target dose in mcg, volume in ml, units on your specific syringe. If any number doesn't match what you're actually drawing, you found the problem.

The Pattern

All five causes share a trait: they're operational failures, not pharmacological ones. They happen when the system around the protocol breaks down. The compounds work. The protocol design works. The execution drifted.

Tolerance is real but rare at therapeutic doses of most peptides. Before changing your protocol, increasing dose, or switching vendors, audit these five operational causes. The answer is usually in your process, not your compounds.

Related

• The invisible degradation loop
• How long do reconstituted peptides last?
• What to track during a peptide cycle

Disclaimer: Educational content, not medical advice. Consult a healthcare provider for protocol guidance.